NASDAQ:ZSAN

Zosano Pharma Competitors

$0.91
+0.14 (+18.28 %)
(As of 04/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.78
Now: $0.91
$0.91
50-Day Range
$0.94
MA: $1.21
$1.47
52-Week Range
$0.33
Now: $0.91
$3.06
Volume3.41 million shs
Average Volume10.00 million shs
Market Capitalization$96.30 million
P/E RatioN/A
Dividend YieldN/A
Beta2.98

Competitors

Zosano Pharma (NASDAQ:ZSAN) Vs. DRRX, NATR, ATNX, MEIP, SYRS, and ATHX

Should you be buying ZSAN stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Zosano Pharma, including DURECT (DRRX), Nature's Sunshine Products (NATR), Athenex (ATNX), MEI Pharma (MEIP), Syros Pharmaceuticals (SYRS), and Athersys (ATHX).

DURECT (NASDAQ:DRRX) and Zosano Pharma (NASDAQ:ZSAN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, analyst recommendations and valuation.

Volatility & Risk

DURECT has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500. Comparatively, Zosano Pharma has a beta of 2.98, meaning that its stock price is 198% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for DURECT and Zosano Pharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
DURECT00603.00
Zosano Pharma00303.00

DURECT currently has a consensus target price of $6.60, suggesting a potential upside of 290.53%. Zosano Pharma has a consensus target price of $2.1667, suggesting a potential upside of 139.15%. Given DURECT's higher probable upside, equities analysts clearly believe DURECT is more favorable than Zosano Pharma.

Insider & Institutional Ownership

53.8% of DURECT shares are owned by institutional investors. Comparatively, 10.1% of Zosano Pharma shares are owned by institutional investors. 5.2% of DURECT shares are owned by insiders. Comparatively, 6.1% of Zosano Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares DURECT and Zosano Pharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DURECT$29.56 million12.99$-20,580,000.00($0.12)-14.08
Zosano PharmaN/AN/A$-37,590,000.00($2.29)-0.40

DURECT has higher revenue and earnings than Zosano Pharma. DURECT is trading at a lower price-to-earnings ratio than Zosano Pharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares DURECT and Zosano Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DURECT-21.85%-33.98%-12.11%
Zosano PharmaN/A-227.55%-79.80%

Summary

DURECT beats Zosano Pharma on 8 of the 12 factors compared between the two stocks.

Nature's Sunshine Products (NASDAQ:NATR) and Zosano Pharma (NASDAQ:ZSAN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, analyst recommendations and valuation.

Insider & Institutional Ownership

78.3% of Nature's Sunshine Products shares are owned by institutional investors. Comparatively, 10.1% of Zosano Pharma shares are owned by institutional investors. 16.0% of Nature's Sunshine Products shares are owned by insiders. Comparatively, 6.1% of Zosano Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Nature's Sunshine Products and Zosano Pharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nature's Sunshine Products$362.21 million1.06$6.76 millionN/AN/A
Zosano PharmaN/AN/A$-37,590,000.00($2.29)-0.40

Nature's Sunshine Products has higher revenue and earnings than Zosano Pharma.

Analyst Recommendations

This is a summary of current ratings and target prices for Nature's Sunshine Products and Zosano Pharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nature's Sunshine Products0000N/A
Zosano Pharma00303.00

Zosano Pharma has a consensus target price of $2.1667, suggesting a potential upside of 139.15%. Given Zosano Pharma's higher probable upside, analysts clearly believe Zosano Pharma is more favorable than Nature's Sunshine Products.

Profitability

This table compares Nature's Sunshine Products and Zosano Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nature's Sunshine Products4.39%11.61%7.14%
Zosano PharmaN/A-227.55%-79.80%

Volatility & Risk

Nature's Sunshine Products has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Comparatively, Zosano Pharma has a beta of 2.98, meaning that its stock price is 198% more volatile than the S&P 500.

Summary

Nature's Sunshine Products beats Zosano Pharma on 8 of the 11 factors compared between the two stocks.

Zosano Pharma (NASDAQ:ZSAN) and Athenex (NASDAQ:ATNX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, earnings, analyst recommendations and dividends.

Insider & Institutional Ownership

10.1% of Zosano Pharma shares are owned by institutional investors. Comparatively, 57.7% of Athenex shares are owned by institutional investors. 6.1% of Zosano Pharma shares are owned by company insiders. Comparatively, 16.3% of Athenex shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Zosano Pharma and Athenex's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zosano PharmaN/AN/A$-37,590,000.00($2.29)-0.40
Athenex$101.23 million3.76$-123,750,000.00($1.67)-2.44

Zosano Pharma has higher earnings, but lower revenue than Athenex. Athenex is trading at a lower price-to-earnings ratio than Zosano Pharma, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Zosano Pharma and Athenex, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zosano Pharma00303.00
Athenex06302.33

Zosano Pharma presently has a consensus price target of $2.1667, suggesting a potential upside of 139.15%. Athenex has a consensus price target of $15.00, suggesting a potential upside of 268.55%. Given Athenex's higher probable upside, analysts plainly believe Athenex is more favorable than Zosano Pharma.

Profitability

This table compares Zosano Pharma and Athenex's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zosano PharmaN/A-227.55%-79.80%
Athenex-75.45%-66.12%-33.81%

Risk & Volatility

Zosano Pharma has a beta of 2.98, indicating that its share price is 198% more volatile than the S&P 500. Comparatively, Athenex has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500.

Summary

Athenex beats Zosano Pharma on 7 of the 12 factors compared between the two stocks.

Zosano Pharma (NASDAQ:ZSAN) and MEI Pharma (NASDAQ:MEIP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, earnings, analyst recommendations and dividends.

Insider & Institutional Ownership

10.1% of Zosano Pharma shares are owned by institutional investors. Comparatively, 67.6% of MEI Pharma shares are owned by institutional investors. 6.1% of Zosano Pharma shares are owned by company insiders. Comparatively, 4.4% of MEI Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Zosano Pharma and MEI Pharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zosano PharmaN/AN/A$-37,590,000.00($2.29)-0.40
MEI Pharma$28.91 million13.16$-46,010,000.00($0.26)-13.00

Zosano Pharma has higher earnings, but lower revenue than MEI Pharma. MEI Pharma is trading at a lower price-to-earnings ratio than Zosano Pharma, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Zosano Pharma and MEI Pharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zosano Pharma00303.00
MEI Pharma01602.86

Zosano Pharma presently has a consensus price target of $2.1667, suggesting a potential upside of 139.15%. MEI Pharma has a consensus price target of $10.60, suggesting a potential upside of 213.61%. Given MEI Pharma's higher probable upside, analysts plainly believe MEI Pharma is more favorable than Zosano Pharma.

Profitability

This table compares Zosano Pharma and MEI Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zosano PharmaN/A-227.55%-79.80%
MEI Pharma-142.81%-33.55%-16.70%

Risk & Volatility

Zosano Pharma has a beta of 2.98, indicating that its share price is 198% more volatile than the S&P 500. Comparatively, MEI Pharma has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500.

Summary

MEI Pharma beats Zosano Pharma on 7 of the 13 factors compared between the two stocks.

Zosano Pharma (NASDAQ:ZSAN) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, earnings, analyst recommendations and dividends.

Insider & Institutional Ownership

10.1% of Zosano Pharma shares are owned by institutional investors. 6.1% of Zosano Pharma shares are owned by company insiders. Comparatively, 14.8% of Syros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Zosano Pharma and Syros Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zosano PharmaN/AN/A$-37,590,000.00($2.29)-0.40
Syros Pharmaceuticals$1.98 million190.83$-75,440,000.00($1.88)-3.26

Zosano Pharma has higher earnings, but lower revenue than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Zosano Pharma, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Zosano Pharma and Syros Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zosano Pharma00303.00
Syros Pharmaceuticals00703.00

Zosano Pharma presently has a consensus price target of $2.1667, suggesting a potential upside of 139.15%. Syros Pharmaceuticals has a consensus price target of $17.00, suggesting a potential upside of 177.32%. Given Syros Pharmaceuticals' higher probable upside, analysts plainly believe Syros Pharmaceuticals is more favorable than Zosano Pharma.

Profitability

This table compares Zosano Pharma and Syros Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zosano PharmaN/A-227.55%-79.80%
Syros Pharmaceuticals-743.58%-111.54%-49.71%

Risk & Volatility

Zosano Pharma has a beta of 2.98, indicating that its share price is 198% more volatile than the S&P 500. Comparatively, Syros Pharmaceuticals has a beta of 2.01, indicating that its share price is 101% more volatile than the S&P 500.

Summary

Syros Pharmaceuticals beats Zosano Pharma on 7 of the 12 factors compared between the two stocks.

Zosano Pharma (NASDAQ:ZSAN) and Athersys (NASDAQ:ATHX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, earnings, analyst recommendations and dividends.

Insider & Institutional Ownership

10.1% of Zosano Pharma shares are owned by institutional investors. Comparatively, 27.9% of Athersys shares are owned by institutional investors. 6.1% of Zosano Pharma shares are owned by company insiders. Comparatively, 12.6% of Athersys shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Zosano Pharma and Athersys' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zosano PharmaN/AN/A$-37,590,000.00($2.29)-0.40
Athersys$5.63 million66.87$-44,580,000.00($0.29)-5.97

Zosano Pharma has higher earnings, but lower revenue than Athersys. Athersys is trading at a lower price-to-earnings ratio than Zosano Pharma, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Zosano Pharma and Athersys, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zosano Pharma00303.00
Athersys00403.00

Zosano Pharma presently has a consensus price target of $2.1667, suggesting a potential upside of 139.15%. Athersys has a consensus price target of $9.00, suggesting a potential upside of 420.23%. Given Athersys' higher probable upside, analysts plainly believe Athersys is more favorable than Zosano Pharma.

Profitability

This table compares Zosano Pharma and Athersys' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zosano PharmaN/A-227.55%-79.80%
AthersysN/A-176.56%-112.67%

Risk & Volatility

Zosano Pharma has a beta of 2.98, indicating that its share price is 198% more volatile than the S&P 500. Comparatively, Athersys has a beta of -1.54, indicating that its share price is 254% less volatile than the S&P 500.

Summary

Athersys beats Zosano Pharma on 7 of the 11 factors compared between the two stocks.


Zosano Pharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
DURECT logo
DRRX
DURECT
1.4$1.69+5.3%$383.97 million$29.56 million-33.79
Nature's Sunshine Products logo
NATR
Nature's Sunshine Products
1.0$19.38+1.7%$383.65 million$362.21 million23.35
Athenex logo
ATNX
Athenex
1.6$4.07+2.0%$380.36 million$101.23 million-2.79Gap Up
MEI Pharma logo
MEIP
MEI Pharma
1.7$3.38+4.7%$380.35 million$28.91 million-5.63
Syros Pharmaceuticals logo
SYRS
Syros Pharmaceuticals
1.3$6.13+0.8%$377.85 million$1.98 million-3.69News Coverage
Athersys logo
ATHX
Athersys
1.3$1.73+5.2%$376.47 million$5.63 million-4.68Analyst Upgrade
Fulcrum Therapeutics logo
FULC
Fulcrum Therapeutics
1.7$11.52+1.0%$376.38 millionN/A-4.00
Paratek Pharmaceuticals logo
PRTK
Paratek Pharmaceuticals
1.5$8.02+3.4%$376.08 million$16.54 million-3.26
Aeglea BioTherapeutics logo
AGLE
Aeglea BioTherapeutics
1.7$7.78+3.5%$373.56 million$3.89 million-4.07
Spruce Biosciences logo
SPRB
Spruce Biosciences
1.6$15.93+0.4%$371.20 millionN/A0.00High Trading Volume
BeyondSpring logo
BYSI
BeyondSpring
1.2$9.44+0.7%$369.50 millionN/A-4.63Analyst Upgrade
Oncorus logo
ONCR
Oncorus
1.7$13.89+1.9%$355.93 millionN/A0.00
BELLUS Health logo
BLU
BELLUS Health
1.7$4.52+2.4%$354.08 million$30,000.00-7.66
Verrica Pharmaceuticals logo
VRCA
Verrica Pharmaceuticals
1.6$13.73+1.1%$349.31 millionN/A-10.40
BioDelivery Sciences International logo
BDSI
BioDelivery Sciences International
2.1$3.42+4.1%$344.95 million$111.39 million24.43
Homology Medicines logo
FIXX
Homology Medicines
1.6$6.71+5.4%$338.77 million$1.67 million-2.46
Theratechnologies logo
THTX
Theratechnologies
1.1$3.56+0.8%$334.07 million$63.22 million-11.48Analyst Report
Frequency Therapeutics logo
FREQ
Frequency Therapeutics
1.5$9.76+2.3%$333.58 million$28.95 million-13.94
Orphazyme A/S logo
ORPH
Orphazyme A/S
1.0$9.52+7.4%$332.74 millionN/A0.00Gap Down
Tonix Pharmaceuticals logo
TNXP
Tonix Pharmaceuticals
1.8$1.03+2.0%$332.02 millionN/A-0.29Gap Up
Oncternal Therapeutics logo
ONCT
Oncternal Therapeutics
1.7$6.64+13.4%$327.78 million$2.42 million-5.82
Hookipa Pharma logo
HOOK
Hookipa Pharma
1.2$12.30+1.7%$319.43 million$11.94 million-7.50High Trading Volume
RedHill Biopharma logo
RDHL
RedHill Biopharma
1.4$6.87+4.2%$318.73 million$6.29 million-3.95
Immunic logo
IMUX
Immunic
1.8$14.08+8.3%$306.23 millionN/A-4.77Analyst Report
CymaBay Therapeutics logo
CBAY
CymaBay Therapeutics
1.6$4.40+5.2%$303.36 millionN/A-4.68
Arbutus Biopharma logo
ABUS
Arbutus Biopharma
1.4$3.14+4.5%$302.01 million$6.01 million-2.55News Coverage
ProQR Therapeutics logo
PRQR
ProQR Therapeutics
1.4$6.00+4.2%$301.23 millionN/A-4.88
Wave Life Sciences logo
WVE
Wave Life Sciences
1.8$6.11+3.4%$299.37 million$15.98 million-1.08
Immunome logo
IMNM
Immunome
1.1$27.25+7.9%$290.49 millionN/A0.00Analyst Upgrade
News Coverage
Sol-Gel Technologies logo
SLGL
Sol-Gel Technologies
1.2$14.19+4.6%$289.33 million$22.90 million-10.67
Trevena logo
TRVN
Trevena
1.3$1.75+2.9%$282.23 million$30,000.00-7.61News Coverage
Gap Down
VistaGen Therapeutics logo
VTGN
VistaGen Therapeutics
1.3$1.96+4.1%$280.95 millionN/A-4.08
Oramed Pharmaceuticals logo
ORMP
Oramed Pharmaceuticals
1.3$9.22+9.5%$278.70 million$2.71 million-15.90Analyst Report
News Coverage
Kezar Life Sciences logo
KZR
Kezar Life Sciences
1.3$5.78+6.6%$277.82 millionN/A-4.62
Kamada logo
KMDA
Kamada
1.4$6.11+1.5%$272.02 million$127.19 million12.73
Mustang Bio logo
MBIO
Mustang Bio
1.6$3.13+3.5%$266.60 millionN/A-2.50Increase in Short Interest
Infinity Pharmaceuticals logo
INFI
Infinity Pharmaceuticals
1.6$3.00+7.3%$265.92 million$3.05 million-4.23News Coverage
VYNE Therapeutics logo
VYNE
VYNE Therapeutics
1.8$5.15+6.6%$264.34 million$10.64 million-1.37
Alpine Immune Sciences logo
ALPN
Alpine Immune Sciences
1.8$11.04+0.2%$263.66 million$1.74 million-7.67
TFF Pharmaceuticals logo
TFFP
TFF Pharmaceuticals
1.4$11.24+0.8%$260.09 millionN/A-4.26
NextCure logo
NXTC
NextCure
1.6$9.14+1.1%$252.26 million$6.35 million-8.09
TLC
Taiwan Liposome
1.2$5.88+1.2%$247.41 million$6.99 million-7.35News Coverage
Tricida logo
TCDA
Tricida
1.9$4.73+2.5%$237.65 millionN/A-0.88Analyst Upgrade
News Coverage
Ovid Therapeutics logo
OVID
Ovid Therapeutics
1.5$3.59+0.3%$236.06 millionN/A-2.55Analyst Downgrade
News Coverage
Gap Up
9 Meters Biopharma logo
NMTR
9 Meters Biopharma
1.8$1.08+3.7%$233.36 millionN/A0.00
Xeris Pharmaceuticals logo
XERS
Xeris Pharmaceuticals
1.6$3.88+1.8%$231.89 million$2.72 million-0.98Increase in Short Interest
PLx Pharma logo
PLXP
PLx Pharma
1.5$10.45+4.2%$227.67 million$570,000.00-8.50
Cerecor logo
CERC
Cerecor
1.8$2.53+7.5%$225.44 million$6.75 million-8.43Analyst Report
News Coverage
Gap Down
Mereo BioPharma Group logo
MREO
Mereo BioPharma Group
1.4$3.27+0.6%$221.68 millionN/A-1.31
MediciNova logo
MNOV
MediciNova
1.2$4.50+2.4%$219.06 millionN/A0.00Upcoming Earnings
This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.